OBJECTIVES The objective of this study was to evaluate the cost-effectiveness of quadripolar versus bipolar cardiac resynchronization defibrillator therapy systems.
However, new technology is usually provided at a higher purchase price than the conventional standard of care, which means that cost-effectiveness and affordability must be considered (12) . Furthermore, the need for £22 billion in savings by 2020 in the United Kingdom (13) and an increased focus on efficiency as a result (14) We set out to assess the cost-effectiveness of quadripolar LV leads compared with bipolar LV leads in patients implanted with a cardiac resynchronization defibrillator therapy device (CRTD) within our previously published registry. We analyzed longerterm health-care utilization costs in terms of hospitalizations that occurred within the 5-year follow-up period to investigate whether the higher purchase price of this new technology was offset by expected reductions in cost arising from a reduction in hospitalizations. We also used mortality, acute coronary syndrome, and heart failure hospitalization data to estimate quality-adjusted life-year (QALY) differences. We performed an economic analysis of the registry data using all hospitalizations that occurred during the follow-up period. The rates of hospitalizations in each year from implantation were multiplied by the national tariff that pertained to the cause of Behar et al.
METHODS
Cost-Effectiveness of Quadripolar vs. Bipolar CRTD F E B R U A R Y 2 0 1 7 : 1 0 7 -1 6 hospitalization ( Table 1) . There was no extrapolation of data or event rates beyond the 5-year follow-up after implantation. Event rates were those that were observed to have occurred in each year; we did not derive transition probabilities that could be used for a Markov model. All events were counted, and some events occurred more than once in individual patients. A probabilistic sensitivity analysis was also undertaken to help understand the impact of parameter uncertainty and determine the probability that quadripolar CRTD was cost-effective. Probabilistic analysis was conducted by inputting data as probability (beta) distributions rather than point estimates and randomly sampling 1,000 values from these distributions. This was performed for all hospitalization episodes in addition to mortality data from our previous work (17) . COSTS. National tariff "enhanced tariff option" prices for 2015 to 2016 (18) were applied to ACS hospitalization, arrhythmia hospitalization, heart failure hospitalization, and lead revision procedures. The base tariff price was multiplied by the local cost factor (market forces factor) for each NHS hospital that implants CRT devices, and the mean of these values was used in the model. Table 1 shows the mean unit cost data used in the calculations per hospitalization, including local cost factors. Online Table 2 shows the equivalent costs in US dollars using a simple conver- Only the mortality difference used in our previous report (17) , utility loss attributable to ACS events, and utility loss attributable to heart failure hospitalizations were used to assess QALY differences between bipolar and quadripolar devices, similar to the methods used in the economic analysis that informed NICE's recent technology appraisal of implantable cardioverter-defibrillators and CRT (19). A baseline EQ-5D utility of 0.8808 was used for a patient with heart failure and a CRT device (range: 0.85 to 0.903), with utility loss because of death being taken as a loss from this value to zero. The utility loss associated with a heart failure admission was calculated, from the work of Swinburn et al. (23) Behar et al.
Cost-Effectiveness of Quadripolar vs. Bipolar CRTD Table 2 .
Patients implanted with a quadripolar lead had a significantly lower absolute number of all-cause hospitalizations (quadripolar: 191 admissions among 309 patients; bipolar: 225 admissions among 287 patients; p < 0.001), as shown in Table 3 . Moreover, the proportion of patients hospitalized at least once was also significantly lower in those implanted with a quadripolar compared with a bipolar lead (42.6% vs.
55.4%, respectively; p ¼ 0.002), as shown in Table 4 . Values are mean AE SD or n (%).
LV ¼ left ventricular; NYHA ¼ New York Heart Association.
Behar et al.
Cost-Effectiveness of Quadripolar vs. Bipolar CRTD lead revisions were similar between the groups (p ¼
NS). Each hospitalization, irrespective of cause, was
counted as a separate event ( Table 3) ; these values were multiplied by the appropriate tariff ( Table 1) to produce health-care utilization costs for each group over the 5-year period. Table 4 represents the proportion of patients implanted with either quadripolar or bipolar leads who had at least 1 admission for the listed reasons.
The absolute values for the hospitalization causes are therefore less than in (Figure 3) . The cost saving was up to £1,000 ($1,500) for purchasing a quadripolar system for the same price as a bipolar system ( Table 5) . Beyond £932 ($1,398), the additional ICER was up to £20,288 ($30,432) ( Figure 3 ). The main findings were as follows:
1. There was a lower absolute number of hospitalizations in patients in whom quadripolar CRTD systems were implanted, predominantly driven by a reduction in readmissions for heart failure and generator replacements. Some patients were hospitalized for the same category more than once, and some not at all. The cost of events was calculated by multiplying the number of events in each year by the cost of the event for that year (i.e., events beyond year 1 were multiplied by the discounted cost for the year in which the event occurred). *Based on the tariff codes in Table 1 .
ACS ¼ acute coronary syndrome; LV ¼ left ventricular; RA ¼ right atrial; RV ¼ right ventricular. Values are n (%).
CI ¼ confidence interval; other abbreviations as in Table 3 .
4. The calculated cost-effectiveness using real-world clinical data (deterministic model) was closely mirrored by the probabilistic sensitivity analysis, which reaffirms confidence in the results.
Multipolar LV leads for CRT delivery have demonstrated high implant success, good capture thresholds at implantation and follow-up, and a low rate of lead displacement (11, 26) . Rates of intraprocedural lead complications appear lower than with conventional bipolar leads (27) . Reduction or even elimination in PNS during medium-term follow-up provides invaluable utility in CRT delivery (9, 15) . We have recently shown a reduction in all-cause mortality associated with quadripolar leads compared with a bipolar lead (17) . Furthermore, rates of reintervention for lead repositioning were lower in those implanted with a quadripolar compared with a bipolar lead (2% vs. 5.2%; p ¼ 0.03), and the radiation dose during implantation was almost one-half (1,028 cGy$cm 2 vs.
1,950 cGy$cm 2 ; p < 0.001).
The lower rates of hospitalization associated with a quadripolar lead in the current study could be driven by the improved efficacy in CRT delivery £0 £20,000 £40,000 £60,000 £80,000 £100,000 £120,000
The x-axis shows the willingness-to-pay threshold (i.e., the incremental cost per QALY gained). Quadripolar (Quad) CRTD is 97.1% likely to be cost-effective at £20,000
($30,000) per QALY gained and 99.3% likely to be cost-effective at £30,000 ($45,000)
per QALY gained. Abbreviations as in Figure 2 . STUDY LIMITATIONS. The data used as the basis of this economic evaluation were derived from a multicenter clinical registry, and the choice of whether quadripolar or bipolar leads were implanted was not subject to a randomization process. However, the approach we have taken reflects current demands in which real-world data are becoming more important to assess the impact that new technologies have actually had on patients and health systems. We took real clinical events that occurred in NHS practice and applied NHS tariffs to them to determine the actual charge and cost-effectiveness. This was an in-study cost-effectiveness analysis, not an extrapolation to a lifetime horizon. We therefore did not assume event rates and did not model beyond the time for which we had gathered follow-up data. We did not perform a Markov model. Wider societal benefit was also not taken into account, which might be a further limitation.
As might be expected, the incremental acquisition cost of quadripolar technology is a strong determinant of the overall incremental costeffectiveness of the 2 therapies. We therefore made an estimate of base cost and performed an analysis either side of the additional purchase cost to account for the variation in procurement acquisition costs. With respect to QALYs, the mortality difference was the strongest driver of the QALY gain associated with quadripolar CRTD. There was a significant difference in the proportions of patients with ischemic heart disease and those not in sinus rhythm (with more such patients in the bipolar group); however, this was corrected for in the multivariate analysis, and mortality remained significantly different.
CONCLUSIONS
In a 5-year time horizon calculated from a UK healthcare system perspective, the additional purchase price of quadripolar CRTD systems is substantially offset by lower health-care utilization costs, which suggests this technology is highly cost-effective compared with bipolar systems. 
